[New drug approval: Trastuzumab-deruxtecan in HER2 positive advanced gastric or gastroesophageal junction cancer after previous treatment with trastuzumab]

Bull Cancer. 2023 Jul-Aug;110(7-8):739-740. doi: 10.1016/j.bulcan.2023.04.006. Epub 2023 May 17.

[Article in French]

Authors

Jeanne Duval¹, Aziz Zaanan²

Affiliations

¹ université Paris Sorbonne, hôpital Saint-Antoine, département d'oncologie digestive, 184, rue du Faubourg-Saint-Antoine, 75012 Paris France. Electronic address: jeanne.duval@aphp.fr.
² Georges-Pompidou European Hospital, Assistance publique-Hôpitaux de Paris, université Paris Cité, Department of Digestive Oncology, 20, rue Leblanc, 75015 Paris cedex, France.

PMID: 37208251
DOI: 10.1016/j.bulcan.2023.04.006

No abstract available

Publication types

Letter

MeSH terms

Antineoplastic Combined Chemotherapy Protocols / adverse effects
Camptothecin / therapeutic use
Drug Approval
Esophagogastric Junction
Humans
Immunoconjugates* / therapeutic use
Neoplasms* / drug therapy
Receptor, ErbB-2 / therapeutic use
Stomach Neoplasms* / drug therapy
Stomach Neoplasms* / genetics
Trastuzumab / therapeutic use

Substances

Trastuzumab
Camptothecin
Immunoconjugates
Receptor, ErbB-2